Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -97.52% is 15% below its 5-year average of -84.52%, around the middle of its 5-year range (-119.98%–-46.71%).
8.07% above its 12-month average of -106.09%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -18.93%.
RETURN ON ASSETS (ROA)
-97.52%
RETURN ON ASSETS (ROA) AVG TTM
-106.09%
RETURN ON ASSETS (ROA) AVG 3Y
-92.87%
RETURN ON ASSETS (ROA) AVG 5Y
-84.52%
RETURN ON ASSETS (ROA) AVG 10Y
-84.07%
RETURN ON ASSETS (ROA) AVG 15Y
-87.40%
RETURN ON ASSETS (ROA) AVG 20Y
-90.45%
CURRENT VS TTM AVG
+8.07%
CURRENT VS 3Y AVG
-5.01%
CURRENT VS 5Y AVG
-15.38%
CURRENT VS 10Y AVG
-16.00%
CURRENT VS 15Y AVG
-11.57%
CURRENT VS 20Y AVG
-7.82%
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-202.48%
vs the sector median at left
Soligenix, Inc.
Market Cap
$5.31M
Return on Assets (ROA)
-97.52%
TTM Avg
-106.09%
3Y Avg
-92.87%
5Y Avg
-84.52%
Market Cap
$5.32M
Return on Assets (ROA)
-30.94%
TTM Avg
-24.01%
3Y Avg
-19.50%
5Y Avg
-23.56%
Market Cap
$5.35M
Return on Assets (ROA)
-161.71%
TTM Avg
-175.21%
3Y Avg
-164.83%
5Y Avg
-138.13%
Market Cap
$5.24M
Return on Assets (ROA)
-104.10%
TTM Avg
-116.11%
3Y Avg
-102.15%
5Y Avg
-84.67%
Market Cap
$5.22M
Return on Assets (ROA)
-123.63%
TTM Avg
-110.43%
3Y Avg
-77.11%
5Y Avg
-65.55%
Market Cap
$5.21M
Return on Assets (ROA)
-71.72%
TTM Avg
-29.50%
3Y Avg
-8.92%
5Y Avg
-8.92%
Market Cap
$5.21M
Return on Assets (ROA)
-106.49%
TTM Avg
-259.99%
3Y Avg
-586.63%
5Y Avg
-434.16%
Market Cap
$5.12M
Return on Assets (ROA)
-1300.98%
TTM Avg
-1108.45%
3Y Avg
-604.75%
5Y Avg
-486.62%
Market Cap
$5.63M
Return on Assets (ROA)
-68.33%
TTM Avg
-234.58%
3Y Avg
-196.81%
5Y Avg
-171.01%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Soligenix, Inc. (SNGX) | $5.31M | -97.52% | -106.09% | -92.87% | -84.52% |
| Gelteq Limited Ordinary Shares (GELS)vs › | $5.32M | -30.94% | -24.01% | -19.50% | -23.56% |
| Lexaria Bioscience Corp. (LEXX)vs › | $5.35M | -161.71% | -175.21% | -164.83% | -138.13% |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.24M | -104.10% | -116.11% | -102.15% | -84.67% |
| Pulmatrix, Inc. (PULM)vs › | $5.22M | -123.63% | -110.43% | -77.11% | -65.55% |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.21M | -71.72% | -29.50% | -8.92% | -8.92% |
| Alzamend Neuro Inc (ALZN)vs › | $5.21M | -106.49% | -259.99% | -586.63% | -434.16% |
| Lunai Bioworks Inc. (LNAI)vs › | $5.12M | -1300.98% | -1108.45% | -604.75% | -486.62% |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.63M | -68.33% | -234.58% | -196.81% | -171.01% |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $4.97M | -367.93% | -1046.51% | -534.79% | -427.52% |
ROA
-97.5%
ROE
-154.1%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -119.98% |
| 2024-12-31 | -92.19% |
| 2023-12-31 | -62.68% |
| 2022-12-31 | -96.63% |
| 2021-12-31 | -46.71% |
| 2020-12-31 | -88.93% |
| 2019-12-31 | -120.32% |
| 2018-12-31 | -84.83% |
| 2017-12-31 | -74.84% |
| 2016-12-31 | -31.61% |
| 2015-12-31 | -106.01% |
| 2014-12-31 | -96.44% |
| 2013-12-31 | -121.70% |
| 2012-12-31 | -88.48% |
| 2011-12-31 | -28.93% |
| 2010-12-31 | -79.70% |
| 2009-12-31 | -64.30% |
| 2008-12-31 | -101.76% |
| 2007-12-31 | -162.93% |
| 2006-12-31 | -580.18% |
| 2005-12-31 | -139.95% |
| 2004-12-31 | -115.87% |
| 2003-12-31 | -84.59% |
| 2002-12-31 | -85.06% |
| 2001-12-31 | -132.51% |
| 2000-12-31 | -35.09% |
| 1999-12-31 | -80.90% |
| 1998-12-31 | -134.57% |
| 1997-12-31 | -16.75% |
| 1996-01-31 | -82.75% |
